Pharmaceutical

Maze Therapeutics raises $115m to advance kidney disease candidates

Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782.

Dec 5, 2024 - 06:00
Maze Therapeutics raises $115m to advance kidney disease candidates
Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782.
Read the original article

Tags:

Previous Article

Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy

Next Article

Ipsen and Biomunex enter agreement for cancer therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Listen: Physicians have a moral and professional obligation to get into ‘good trouble’

Opinion: Listen: Physicians have a moral and profession...

Jun 14, 2023

Izokibep by Acelyrin for Panuveitis: Likelihood of Appr...

Jun 5, 2023

STAT+: Key Senate panel considers Medicare bonuses for hospitals that prevent drug shortages

STAT+: Key Senate panel considers Medicare bonuses for ...

Jan 26, 2024